NSAID Use Linked to Increased Venous Thromboembolism RiskLast Updated: June 08, 2011. The use of nonselective nonsteroidal anti-inflammatory drugs or cyclooxygenase-2-selective inhibitors is associated with an increased risk of venous thromboembolism, according to a study published online May 18 in the Journal of Thrombosis and Haemostasis.
WEDNESDAY, June 8 (HealthDay News) -- The use of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2-selective inhibitors (COX2Is) is associated with an increased risk of venous thromboembolism (VTE), according to a study published online May 18 in the Journal of Thrombosis and Haemostasis.
Morten Schmidt, from the Aarhus University Hospital in Denmark, and colleagues examined the association between the use of nonselective NSAIDs or COX2Is and the risk of VTE. Based on data from the Danish National Patient Registry, the authors identified 8,368 patients with a first hospital VTE diagnosis from 1999 to 2006. Each case was age- and gender-matched with 10 controls (82,218). The use of NSAIDs at the time of diagnosis (current use) or prior to diagnosis (recent use) and co-medications was determined from the prescription database, with current use being further categorized as new use or long-term use.
The investigators found that, compared to no use, the adjusted incidence rate ratio (IRR) correlating current nonselective NSAID use and current COX2I use with VTE was 2.51 and 2.19, respectively. The increases were considerably smaller for recent users compared to current users. For long-term users, the adjusted IRR for nonselective NSAIDs and COX2Is was 2.06 and 1.92, respectively. Increased risks were seen for unprovoked VTE, deep venous thrombosis, pulmonary embolism, and individual NSAIDs.
"Use of nonselective NSAIDs or COX2Is was associated with two-fold or more increased risk of venous thromboembolism," the authors write.
|Previous: Subcutaneous Insulin Promotes Liver Glucose Metabolism||Next: Mohs Surgery Effective for Cutaneous Leiomyosarcoma|
Reader comments on this article are listed below. Review our comments policy.